Clinical trials: Cerebral Small Vessels Disease
Ischemic Stroke
Improved Prediction of Recurrent Stroke and Detection of Small Volume Stroke
Rationale: Over 20.000 people suffer an ischemic stroke in the Netherlands each year. Large artery occlusions are easy to identify and can be treated with endovascular clot removal.
- Trial name
- ENCLOSE (NCT04019483)
- Where
- 3 sites in Netherlands
- Volunteers
- 439 people
- Sponsor
- UMC Utrecht
Fabry Disease
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity
This study will collect data needed to design a treatment trial for patients with Fabry disease using the experimental drug AT-1001.
- Trial name
- NCT00106912
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Fabry Disease
Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting
PEGASO is an observational study designed to collect prospective data on the effectiveness and safety of pegunigalsidase alfa in adult patients with Fabry disease, being treated or planning to start treatment, under real-world…
- Trial name
- PEGASO (NCT07109375)
- Testing
- pegunigalsidase alfa
- Where
- 7 sites in Italy
- Volunteers
- 75 people
- Sponsor
- Chiesi Italia
Cerebrovascular Disease Small Vessel
Study On the Expression Level and Clinical Significance of VISTA in Patients With Vascular Cognitive Impairment
1. Explore the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cardiovascular risk factors; 2.
- Trial name
- NCT06342661
- Testing
- Neuropsychological testing
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
CADASIL
Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL
This study is a single-center, prospective, single-arm, self-controlled clinical trial designed to assess the safety and efficacy of edaravone dexborneol sublingual tablets for blood-brain barrier (BBB) dysfunction in patients…
- Trial name
- NCT07692399
- Testing
- Edaravone Dexborneol Sublingual Tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Fabry Disease, Proteinuria
Antiproteinuric Agents and Fabry Disease
Fabry disease is a rare disorder that often has kidney involvement with increased urine protein excretion. Proteinuria is recognized as an important risk factor for progression of chronic kidney disease.
- Trial name
- NCT00343577
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Alabama at Birmingham
Cerebral Small Vessel Diseases, Dementia, Mixed
Dementia Risk Registry Across the Multidimensional Lifespan: A 10-Year Study
Age-related cerebral small-vessel disease (CSVD) is a major cause of dementia, predominantly affecting individuals over 60 years of age, with a prevalence exceeding 70% in the elderly population.
- Conditions
- Cerebral Small Vessel Diseases, Dementia, Mixed, Health Behavior, Health Behavior, Risky
- Trial name
- DREAM-10 (NCT06164262)
- Testing
- Individuals with CSVD
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Zhejiang Provincial People's Hospital
Pain, Fabry's Disease
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains
Fabry disease (FD) is a rare X-linked multisytemic lysosomal disorder caused by alpha-galactosidase deficiency. Globotriaosylcéramide (Gb3) deposits are observed in almost all tissues examined.
- Trial name
- DOUFAB (NCT01178164)
- Testing
- Blood sampling for biological and genetic analysis
- Where
- France
- Volunteers
- 137 people
- Sponsor
- University Hospital, Bordeaux
Fabry Disease
Alternative Dosing and Regimen of Replagal to Treat Fabry Disease
The main goal of this study is to assess the pharmacodynamic effects of different or more frequent doses of Replagal compared to the standard dosing regimen.
- Trial name
- NCT00075244
- Testing
- Replagal
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Wegener Granulomatosis, Microscopic Polyangiitis
Efficacy Study of Two Treatments in the Remission of Vasculitis
Study of the efficacy of rituximab for maintenance treatment in systemic ANCA-associated vasculitis: prospective, multicenter, controlled, randomized comparative study of rituximab versus azathioprine
- Trial name
- MAINRITSAN (NCT00748644)
- Testing
- Rituximab, Azathioprine
- Where
- France
- Volunteers
- 117 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
RATIONALE: An Opioid Titration Order Sheet that allows healthcare providers to adjust the dose and schedule of pain medication may help improve pain treatment for patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00666211
- Testing
- educational intervention, Titrated pain management, questionnaire administration
- Where
- 11 sites in United States
- Volunteers
- 98 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Ischemic Stroke Hospitalized
Fabry : National Initiative of Screening
Fabry disease is a genetic disease due to an enzymatic deficit. A screening of this disease allows patients to benefit from an enzyme replacement therapy and prevent the occurrence of life threatening manifestations such as an…
- Trial name
- FIND (NCT00484549)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 889 people
- Sponsor
- University Hospital, Clermont-Ferrand
Fabry Disease
Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy
FD is pan-ethnic. Its reported annual incidence of 1 in 100,000 may underestimate the true prevalence of the disease. Indeed, recently, in addition with affected males FD developing a "classic" phenotype, " cardiac variant " and…
- Trial name
- FABRY (NCT03230149)
- Testing
- Measurements of the alpha-GAL enzyme activity
- Where
- France
- Volunteers
- 379 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Fabry Disease, End Stage Renal Disease
Study of the Prevalence of Fabry Disease in French Dialysis Patients
Fabry Disease (FD) is a rare genetic lysosomal storage disease including an X-linked mutation and characterized by an alpha-galactosidase A (GLA) deficiency.
- Conditions
- Fabry Disease, End Stage Renal Disease, Renal Dialysis
- Trial name
- FABRYDIAL (NCT02843334)
- Testing
- Dried blood spot (DBS) sampling
- Where
- 5 sites in France
- Volunteers
- 6,000 people
- Sponsor
- Hospices Civils de Lyon
Angiokeratomas, Chronic Kidney Disease
Biomarker for Patients With Fabry Disease (BioFabry)
Development of a new mass spectrography-based biomarker for the early and sensitive diagnosis of Fabry disease from the blood
- Conditions
- Angiokeratomas, Chronic Kidney Disease, Ocular Abnormalities, Hearing Loss
- Trial name
- BioFabry (NCT02778295)
- Where
- 3 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Fabry Disease, Proteinuria
The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study
The primary hypothesis is that titration of ACE inhibitor and Angiotensin Receptor Blockers (ARBs)to reduce urine protein excretion to < 500 mg per day in Fabry Patients receiving agalsidase beta therapy at 1 mg/kg every two…
- Trial name
- FAACET (NCT00446862)
- Testing
- enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers
- Where
- 6 sites in United States, Slovenia
- Volunteers
- 36 people
- Sponsor
- University of Alabama at Birmingham
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when taken with methotrexate in the induction of remission in ANCA-Associated Small Vessel Vasculitis.
- Trial name
- BIANCA-SC (NCT01598857)
- Testing
- Blisibimod
- Sponsor
- Anthera Pharmaceuticals
Polyarteritis Nodosa, Microscopic Polyangiitis
CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors
To assess the efficacy of systemic corticosteroids alone as first-line treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors as defined by the five-factor score (FFS=0), and to compare the…
- Trial name
- NCT00400075
- Testing
- azathioprine, cyclophosphamide
- Where
- Switzerland
- Volunteers
- 124 people
- Sponsor
- Hospices Civils de Lyon
Mitochondrial Myopathy, MELAS Syndrome
Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia
OBJECTIVES: I. Study the metabolism of pyruvate and related problems in patients with lactic acidemia. II. Define the nature of the metabolic defect.
- Conditions
- Mitochondrial Myopathy, MELAS Syndrome, Lactic Acidosis
- Trial name
- NCT00004353
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Center for Research Resources (NCRR)
Fabry Disease
Real World Evidence Study of Danish Fabry Patients
Fabry is a rare X-linked metabolic lysosomal disorder caused by deficiency in the enzyme α-galactosidase A (alpha-Gal A) by mutations in the GLA gene, encoding the alpha-Gal A enzyme, which catalyses glycosphingolipids, namely…
- Trial name
- RWE-FABRY (NCT06303466)
- Where
- Denmark
- Volunteers
- 115 people
- Sponsor
- Caroline Michaela Kistorp